News

Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. The trial evaluated pembrolizumab at doses of 2mg/kg every three

Highlights • Lusomedicamenta, together with its subsidiary, had twelve month revenues and adjusted EBITDA for non-recurring items to end September 2014 of EUR 50.7million (SEK 456.3 million) and

The company said that due to its safety profile, the use of Lemtrada should be reserved for patients who have had an inadequate response to two or more

The new 30,000m² facility, to be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant, will house six 15,000l bioreactors, purification area as well as

Around £4m has been set aside by GSK as initial funding round, which will support successful proposals from researchers in Côte d’Ivoire, Cameroon, Ghana, the Gambia, Nigeria, Kenya,

The company sNDA has been granted priority review status by the FDA and it was based on the results of a three-week monotherapy trial in 403 pediatric patients,

As per the auction process, Aurobindo emerged as best bidder with a bid of $132.5m to acquire the assets of Natrol with an agreement to take on certain

The Notice of Allowance is for U.S. Patent Application No. 14/230,067, "Methods for Treatment of Attention Deficit Hyperactivity Disorder", which relates to HLD-200, including its unique pharmacokinetic profile.

This award enables Integral Molecular to understand how human antibodies protect (or fail to protect) against these viruses. Using its proprietary Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular